Opinion
Video
Author(s):
Panelists discuss how matching-adjusted indirect comparisons (MAIC) of ALK inhibitors and the FDA approval of ensartinib in December 2024 influence frontline treatment selection for ALK+ non–small cell lung cancer (NSCLC).
Comparative Data Analysis and Ensartinib Approval
Key Themes:
Notable Insights:
Dr Lovly provided an overview of the eXalt3 study following ensartinib’s recent FDA approval in December 2024
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.